REGN:NSD-Regeneron Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 736.23

Change

+0.87 (+0.12)%

Market Cap

USD 81.59B

Volume

0.23M

Avg Analyst Target

USD 740.87 (+0.63%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


REGN Stock Forecast & Price:
Based on the Regeneron Pharmaceuticals Inc stock forecasts from 19 analysts, the average analyst target price for Regeneron Pharmaceuticals Inc is USD 740.87 over the next 12 months. Regeneron Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Regeneron Pharmaceuticals Inc is Slightly Bullish , which is based on 9 positive signals and 4 negative signals. At the last closing, Regeneron Pharmaceuticals Inc’s stock price was USD 736.23. Regeneron Pharmaceuticals Inc’s stock price has changed by -0.07% over the past week, -1.49% over the past month and +13.58% over the last year.

About Regeneron Pharmaceuticals Inc (REGN:NSD)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroi ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
GILD Gilead Sciences Inc

+0.84 (+0.98%)

USD106.90B 32.28 22.67
VRTX Vertex Pharmaceuticals Inc

-3.18 (-1.01%)

USD82.52B 24.98 17.08
MRNA Moderna Inc

-0.41 (-0.23%)

USD68.99B 3.18 4.44
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

-1.38 (-0.88%)

USD37.91B 3.79 1.71
GMAB Genmab AS

+0.34 (+0.77%)

USD29.03B 36.52 3.47
ALNY Alnylam Pharmaceuticals Inc

+4.23 (+2.03%)

USD25.76B N/A -27.59
SGEN Seagen Inc

-0.52 (-0.42%)

USD23.02B 55.02 -41.49
ARGX argenx NV ADR

-2.93 (-0.78%)

USD20.68B N/A -20.30
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing REGN

Symbol Name Weight Mer Price(Change) Market Cap
BIOT:LSE L&G Pharma Breakthrough U.. 4.91 % 0.75 %

N/A

USD8.18M
UBIO ProShares UltraPro Nasdaq.. 4.54 % 0.95 %

N/A

USD0.02B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.02 (+0.26%)

USD0.46B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.01 (-0.11%)

USD0.46B
MINV:LSE iShares VI Public Limited.. 0.00 % 0.35 %

+20.00 (+0.43%)

USD3.79B
MVOL:LSE iShares Edge MSCI World M.. 0.00 % 0.35 %

+0.01 (+0.02%)

USD3.77B
VMOM:LSE Vanguard Global Momentum .. 0.00 % 0.00 %

N/A

USD0.07B
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.59 %

-0.05 (-0.73%)

USD0.01B
XDEB:LSE db x-trackers MSCI World .. 0.00 % 0.25 %

+10.50 (+0.34%)

USD0.50B
XMVU:LSE Xtrackers MSCI USA Minimu.. 0.00 % 0.20 %

+0.07 (+0.15%)

USD5.16M
IQQ0:F iShares VI Public Limited.. 0.00 % 0.35 %

+0.01 (+0.02%)

USD4.12B
SXR0:F iShares VI Public Limited.. 0.00 % 0.35 %

+0.01 (+0.13%)

N/A
XDEB:F db x-trackers MSCI World .. 0.00 % 0.25 %

+0.01 (+0.01%)

USD0.50B
BBH VanEck Biotech ETF 0.00 % 0.35 %

+0.18 (+0.11%)

USD0.48B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.02 (+0.35%)

USD0.46B
XDEB:XETRA db x-trackers MSCI World .. 0.00 % 0.25 %

+0.07 (+0.18%)

USD0.50B
BIOT Biotech Acquisition Co 0.00 % 0.75 %

N/A

USD0.29B
EQOP Natixis ETF Trust II - Na.. 0.00 % 0.90 %

-0.01 (-0.04%)

USD9.17M
HHL-B:CA Harvest Healthcare Leader.. 0.00 % 0.99 %

+0.05 (+0.57%)

N/A
STNC Stance Equity ESG Large C.. 0.00 % 0.85 %

+0.05 (+0.19%)

USD0.04B
FBT:LSE First Trust Global Funds .. 0.00 % 0.60 %

+6.80 (+0.44%)

USD6.48M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.60 %

+0.02 (+0.13%)

USD6.48M
AGNG Global X Aging Population.. 0.00 % 0.50 %

+0.03 (+0.10%)

USD0.04B
ILDR First Trust Exchange-Trad.. 0.00 % 0.75 %

+0.03 (+0.23%)

USD2.95M
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.19 %

-0.01 (-0.05%)

USD0.02B
IQQ0:XETRA iShares Edge MSCI World M.. 0.00 % 0.35 %

+0.11 (+0.20%)

USD3.63B
AGES:LSE iShares IV Public Limited.. 0.00 % 0.40 %

+1.50 (+0.28%)

USD0.71B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.46B
XMW:CA iShares MSCI Min Vol Glob.. 0.00 % 0.48 %

+0.53 (+1.16%)

USD0.16B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+0.35 (+0.59%)

USD0.10B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

-0.06 (-0.31%)

USD6.20M
CNCR Loncar Cancer Immunothera.. 0.00 % 0.79 %

-0.13 (-0.92%)

USD0.02B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.55 %

+1.02 (+0.67%)

USD1.42B
IBB iShares Biotechnology ETF 0.00 % 0.44 %

+0.27 (+0.20%)

USD8.86B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

-0.03 (-0.15%)

USD0.19B
LNGR Global X Aging Population.. 0.00 % 0.50 %

N/A

USD0.04B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

-0.09 (-0.14%)

USD0.26B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

+0.42 (+0.54%)

USD0.33B
PXLG Invesco S&P 500 GARP ETF 0.00 % 0.35 %

N/A

USD0.26B
XMY:CA iShares Edge MSCI Min Vol.. 0.00 % 0.47 %

+0.07 (+0.26%)

USD0.02B
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

-0.06 (-0.11%)

USD0.02B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
HHL:CA Healthcare Leaders Income.. 0.00 % 0.99 %

+0.03 (+0.36%)

USD0.33B
HERS:CA Evolve North American Gen.. 0.00 % 0.40 %

N/A

USD3.37M
ENTR ERShares Entrepreneur ETF 0.00 % 0.49 %

-0.03 (-0.34%)

USD0.03B
CLRG IQ Chaikin U.S. Large Cap.. 0.00 % 0.25 %

+0.02 (+0.06%)

USD0.28B
UTRN Vesper U.S. Large Cap Sho.. 0.00 % 0.75 %

+0.03 (+0.11%)

USD0.07B
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

-0.13 (-0.47%)

USD0.18B
HTEC Robo Global® Healthcare .. 0.00 % 0.68 %

+0.04 (+0.13%)

USD0.10B
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.99 %

+0.02 (+0.23%)

N/A
HERS-B:CA Evolve North American Gen.. 0.00 % 0.40 %

N/A

USD3.37M
AGED:LSE iShares Ageing Population.. 0.00 % 0.40 %

N/A

USD0.71B
KONG Formidable Fortress ETF 0.00 % 0.89 %

-0.04 (-0.15%)

USD0.02B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.58% 90% A- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.58% 90% A- 92% A-
Trailing 12 Months  
Capital Gain 14.44% 90% A- 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.44% 90% A- 91% A-
Trailing 5 Years  
Capital Gain 91.30% 85% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 91.30% 85% B 83% B
Average Annual (5 Year Horizon)  
Capital Gain 21.11% 81% B- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.11% 81% B- 82% B-
Risk Return Profile  
Volatility (Standard Deviation) 35.59% 66% D 45% F
Risk Adjusted Return 59.31% 97% A+ 91% A-
Market Capitalization 81.59B 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 15.59 31% F 54% F
Price/Book Ratio 3.75 28% F 23% F
Price / Cash Flow Ratio 11.52 5% F 21% F
EV/EBITDA 11.88 3% F 20% F
Management Effectiveness  
Return on Equity 27.76% 97% A+ 92% A-
Return on Invested Capital 45.60% 92% A- 93% A
Return on Assets 15.72% 99% A+ 98% A+
Debt to Equity Ratio 10.55% 62% D- 68% D+
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.39 66% D 56% F
Short Percent 1.72% 66% D 57% F
Beta 0.20 88% B+ 91% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.